522 related articles for article (PubMed ID: 29457796)
1. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
Spinello A; Borišek J; Malcovati L; Magistrato A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
[TBL] [Abstract][Full Text] [Related]
3. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
5. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
6. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
[TBL] [Abstract][Full Text] [Related]
7. A Small-Molecule Splicing Modulator Targets Spliceosome-Mutant Cells.
Cancer Discov; 2018 Apr; 8(4):384. PubMed ID: 29500297
[TBL] [Abstract][Full Text] [Related]
8. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
9. Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans.
Rioux N; Smith S; Colombo F; Kim A; Lai WG; Nix D; Siu YA; Schindler J; Smith PG
Xenobiotica; 2020 Sep; 50(9):1101-1114. PubMed ID: 31902291
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators.
Aird D; Teng T; Huang CL; Pazolli E; Banka D; Cheung-Ong K; Eifert C; Furman C; Wu ZJ; Seiler M; Buonamici S; Fekkes P; Karr C; Palacino J; Park E; Smith PG; Yu L; Mizui Y; Warmuth M; Chicas A; Corson L; Zhu P
Nat Commun; 2019 Jan; 10(1):137. PubMed ID: 30635584
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
Zhang D; Meng F
ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
[TBL] [Abstract][Full Text] [Related]
12. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
[TBL] [Abstract][Full Text] [Related]
13. Modulating splicing with small molecular inhibitors of the spliceosome.
Effenberger KA; Urabe VK; Jurica MS
Wiley Interdiscip Rev RNA; 2017 Mar; 8(2):. PubMed ID: 27440103
[TBL] [Abstract][Full Text] [Related]
14. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
16. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
17. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated minor intron splicing in cancer.
Nishimura K; Yamazaki H; Zang W; Inoue D
Cancer Sci; 2022 Sep; 113(9):2934-2942. PubMed ID: 35766428
[TBL] [Abstract][Full Text] [Related]
19. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
20. Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin B
Biochem Pharmacol; 2021 Jul; 189():114039. PubMed ID: 32417188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]